6ER-007 Impact of optimising use of carbapenem antibiotics programme
| Autor: | B Tauste Hernández, S Cañizares Paz, P Nieto Guindo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Imipenem medicine.drug_class business.industry Antibiotics Antimicrobial medicine.disease Meropenem Pneumonia chemistry.chemical_compound Antibiotic resistance chemistry Section 6: Education and research Internal medicine medicine Medical prescription business Ertapenem medicine.drug |
| Zdroj: | Eur J Hosp Pharm |
| Popis: | Background Appropriate use of antimicrobials is very complex because of the difficulty in the management of infectious diseases and the spread of antibiotic resistance Purpose To analyse the use of carbapenems antibiotics based on the criteria of infection by extended spectrum beta-lactamases microorganisms (ESBL) and the empirical guide of antibiotics of a third-level hospital Material and methods Prospective observational study in a third-level hospital from 1 to 31 March 2017. All admitted patients who started antibiotic treatment with imipenem, meropenem or ertapenem were included. The indication of antibiotic therapy was evaluated based on ESBL criteria and empirical hospital treatment guidelines. In patients who did not meet these criteria, a recommendation was made to the physician to consider another therapeutic option. Variables collected: age, sex, type of infection, culture, type of intervention (dose adjustment, change of antibiotic, suspension of treatment) and service Results One hundred and twenty-nine patients were included. Average age: 64.21 years (2–92); 40.3% females (n=52) and 59.7% males (n=77). One hundred and thirty-four prescriptions were evaluated (67 meropenem, 53 imipenem and 14 ertapenem), of which 44% (n=59) were considered inadequate and optimisable, and a recommendation was made. The services with the most prescriptions evaluated were: internal medicine (26.86%), general surgery (22.38%), ICU (11.94%) and pneumology (11.19%). The most common clinical syndromes for these prescriptions were pneumonia (33%), intra-abdominal infections (23%), urinary tract infections (12%) and skin and soft tissue infections (11%). Microbiological samples were obtained in 70.89% of the patients, of which 46.31% were positive. Regarding the recommendations made, 83.1% (n=49) were a change in treatment, 10.2% (n=6) dose adjustment and 6.7% (n=4) was to suspend antimicrobial agents. Forty-five per cent of them were accepted. Conclusion Although the degree of acceptance of the intervention must be improved, impressive action by pharmacists contributed to optimising the use of restricted antibiotics, and reducing their use in cases where they were not indicated or where other alternatives existed. No conflict of interest |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|